NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2025
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIOXA HD/EPIOXA KIT is a riboflavin 5-phosphate ophthalmic solution approved by the FDA in October 2025 for ocular indications. This small-molecule eye drop formulation leverages riboflavin's photochemical properties to address corneal and anterior segment pathology. The exact therapeutic mechanism and approved indications are under clinical evaluation by sponsor Glaukos.
LOE Approaching2.3 years to LOE
Early-stage product with imminent loss of exclusivity (2028), limiting long-term commercial team expansion and requiring rapid market penetration strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on EPIOXA HD/EPIOXA KIT at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.